ArriVent BioPharma, Inc. (AVBP)
After hours:
| Previous close | 17.36 |
| Open | 17.54 |
| Bid | 17.81 x 200 |
| Ask | 18.04 x 200 |
| Day's range | 17.47 - 17.99 |
| 52-week range | 14.35 - 25.95 |
| Volume | |
| Avg. volume | 178,925 |
| Market cap | 602.553M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 30.20 |
GlobeNewswireArriVent BioPharma Reports First Quarter 2024 Financial Results
Presented preclinical firmonertinib (formerly furmonertinib) data at the 2024 American Association for Cancer Research (“AACR”) Annual MeetingDosed first patient in Phase 1b combination study of firmonertinib and ICP-189 for advanced or metastatic non-small cell lung cancer (“NSCLC”) with epidermal growth factor receptor (“EGFR”) classical mutationsStrong financial position with cash and cash equivalents of $317.4 million as of March 31, 2024 NEWTOWN SQUARE, Pa., May 08, 2024 (GLOBE NEWSWIRE) --
- GlobeNewswire
ArriVent Appoints Kristine Peterson to its Board of Directors
NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors. Ms. Peterson brings over 30 years of biopharmaceutical leadership experience, and currently serves on the Boards of public companies Immunocore, Inc. and Enanta Pharmaceuticals. “We are thrilled for Kris to join our Boa
- GlobeNewswire
ArriVent BioPharma Reports Full Year 2023 Financial Results
Company progresses the development of furmonertinib with a data readout planned for 2024Furmonertinib granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration Completed $201 million initial public offering (“IPO”) in January 2024 NEWTOWN SQUARE, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, to
